What ARA-290 is
ARA-290 is a peptide that remains in the research stage and does not have an approved drug label. No indications, mechanism of action, or brand names have been established through an approved labeling process for this compound.
Trial footprint
ARA-290 has been studied in 4 registered clinical trials. Sample studies include a completed trial examining corneal nerve fiber density and neuropathic symptoms in subjects with sarcoidosis, a completed trial evaluating cognitive and neural effects, and a terminated trial that had been assessing use in diabetic macular oedema. These trials illustrate the range of conditions researchers have investigated, but their inclusion here does not indicate that ARA-290 is effective or safe for any use.
FAQ
No. ARA-290 is an investigational compound with no approved drug label. It has not been reviewed or approved by the FDA for any medical use.
Registered trials have examined ARA-290 in the context of corneal nerve fiber density and neuropathic symptoms in sarcoidosis, cognitive and neural effects, and diabetic macular oedema. One of these trials was terminated before completion. These studies reflect research interest, not established effectiveness.
There are 4 registered clinical trials involving ARA-290. These vary in phase and status, including completed and terminated studies.
ARA-290 remains an unapproved, investigational compound. Research into its effects continues through clinical trials, but no regulatory body has approved it for therapeutic use.
This overview does not provide dosing or administration information, since ARA-290 is not an approved product. Any use outside of a registered clinical trial falls outside established medical guidance.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov trial registry
Updated 2026-09-19